Phanes Therapeutics and BeiGene Partner on Phase I Study of PT199
Sino-US biotech Phanes Therapeutics Inc. announced a clinical study cooperation and supply agreement with China-based...
HKG: 6160
BeiGene to Present Final PFS Results for Brukinsa at ASH Meeting
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced plans to present...
BeiGene’s Brukinsa Receives EC Approval for CLL Treatment
China-based biotech BeiGene Ltd. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced receiving marketing approval...
Peru Approves BMS’s Reblozyl and BeiGene’s Brukinsa
Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) has approved Bristol-Myers Squibb’s (BMS; NYSE:...
BeiGene’s Brukinsa Receives Marketing Approval in Brazil
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that it has...
BeiGene Reports 88% YOY Revenue Growth in Q3 2022
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) released its Q3 2022 earnings...
BeiGene’s Brukinsa Receives EU Marketing Approval for Marginal Zone Lymphoma
China-based biotech BeiGene Inc. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced receiving marketing approval from...
BeiGene’s Brukinsa Receives Multiple Marketing Approvals in Latin America
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced receiving multiple marketing approvals...
BeiGene’s Brukinsa Receives Positive CHMP Opinion for CLL Approval
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced receiving a positive opinion...
BeiGene’s Brukinsa Outperforms Imbruvica in Phase III ALPINE Study
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that its Bruton’s...
BeiGene Partners with Amoy Diagnostics for Companion Diagnostics Development
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has entered into a partnership...
BeiGene Partners with Immune-Onc for Clinical Development of Myeloid Checkpoint Inhibitors
China-based biotech BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has entered into a clinical study...
BeiGene’s Brukinsa Receives New EU and UK Indications for BTK Inhibitor
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has received two new indication...
BeiGene’s Tislelizumab Meets Primary Endpoint in HCC Study at ESMO
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) presented the latest results of the global Phase...
China-U.S. Listing Agreement Clears Path for Chinese Firms to Stay Listed in the U.S.
China and the United States are nearing an agreement that would allow Chinese firms to...
BeiGene’s Tislelizumab Receives 11th NMPA Filing for First-Line Esophageal Cancer
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the National Medical Products Administration (NMPA)...
BeiGene Partners with Ontada to Accelerate RWE Development in US Oncology Market
China-based biotech company BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced that it has signed...
BeiGene Partners with Jilin Cancer Hospital for Cancer Drug Development
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has entered into a clinical study partnership...
BeiGene’s Tislelizumab Meets Primary Endpoint in Global HCC Study
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the global Phase III RATIONALE 301...
BeiGene’s Q2 2022 Revenues Surge 120%, Brukinsa Sales Triple
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) reported its financial results for Q2 2022, recording...